Literature DB >> 334226

Controlled randomized group comparison of nomifensine and imipramine in depressive illness.

A Forrest, A Hewett, P Nicholson.   

Abstract

1. Nomifensine, an isoquinoline dopaminergic agonist, was investigated in a randomized double-blind group comparison with imipramine, in 40 out-patients with depression. 2. Assessments were made at weekly intervals for 4 weeks using the Hamilton Depression Scale and the Beck Depression Inventory. Blood, kidney and liver function were also monitored weekly. 3. Nomifensine was shown to be at least as effective as imipramine in relieving depression and to relieve tha anxiety component of the disease significantly more rapidly. Neither drug produced serious unwanted effects.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 334226      PMCID: PMC1429136          DOI: 10.1111/j.1365-2125.1977.tb05755.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Actions of dopaminergic agonists on motor function.

Authors:  B Costall; R J Naylor
Journal:  Adv Neurol       Date:  1975

2.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

3.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

4.  [Pharmacological research on maprotiline a new drug with antidepressive effects].

Authors:  V Baltzer; A Delini-Stula; H J Bein
Journal:  Boll Chim Farm       Date:  1973-09

5.  Effect of nomifensine on motor activity, dopamine turnover rate and cyclic 3',5;-adenosine monophosphate concentrations of rat striatum.

Authors:  H J Gerhards; A Carenzi; E Costa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  A critical look at antidepressant drug trials.

Authors:  P Leyburn
Journal:  Lancet       Date:  1967-11-25       Impact factor: 79.321

7.  [8-amino-4-phenyl-1,2,3,4-tetrahydroisoquinolines, a new group of antidepressive psycholeptic drugs].

Authors:  I Hoffmann; G Ehrhart; K Schmitt
Journal:  Arzneimittelforschung       Date:  1971-07

8.  Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action.

Authors:  J T Coyle; S H Snyder
Journal:  Science       Date:  1969-11-14       Impact factor: 47.728

9.  Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons.

Authors:  A S Horn; J T Coyle; S H Snyder
Journal:  Mol Pharmacol       Date:  1971-01       Impact factor: 4.436

10.  Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum.

Authors:  P Hunt; M Kannengiesser; J Raynaud
Journal:  J Pharm Pharmacol       Date:  1974-05       Impact factor: 3.765

View more
  5 in total

1.  Assessment of the anticholinergic effects of antidepressants in a single-dose cross-over study of salivation and plasma levels.

Authors:  L Clemmesen; P L Mikkelsen; H Lund; T G Bolwig; O J Rafaelsen
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 2.  A comparison of active drugs for the treatment of dysthymia.

Authors:  M Silva de Lima; M Hotopf
Journal:  Cochrane Database Syst Rev       Date:  2003

3.  A comparison of the pharmacodynamic profiles of nomifensine and amitriptyline in normal subjects.

Authors:  M Y Chan; R Ehsanullah; J Wadsworth; J McEwen
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

4.  The effects of antidepressants on the autonomic nervous system--a current investigation.

Authors:  Y Ikeda; S Nomura; Y Sawa; T Nakazawa
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

5.  Nomifensine: A review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-07       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.